GlassScriptPhysician profile
Alex B Lipowich
NPI 1083640734
$2,046.40
in general payments reported to CMS, 2019-2025
23 companies · $786 in 2025
The $786 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.93 · 2020: $117 · 2021: $187 · 2022: $199 · 2023: $213 · 2024: $473 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $266.49 | 2019-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima, Acessa Provu System |
| Exeltis, USA INC. | $252.93 | 2024-2025 | Slynd, Tyblume |
| Amgen INC. | $210.58 | 2025 | Evenity, Prolia |
| Novo Nordisk INC | $210.05 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $131.15 | 2024-2025 | Veozah |
| Abbvie INC. | $129.67 | 2020-2023 | |
| Agile Therapeutics, INC. | $129.58 | 2021-2024 | Twirla |
| Exact Sciences Corporation | $115.37 | 2023-2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $105.81 | 2023-2025 | |
| Myriad Women'S Health, INC. | $69.85 | 2023 | |
| Shield Therapeutics INC | $64.00 | 2024 | |
| Organon LLC | $56.38 | 2024-2025 | Nexplanon |
| Coopersurgical, INC. | $54.36 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $45.92 | 2019-2020 | |
| Therapeuticsmd, INC. | $33.81 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $28.31 | 2022 | |
| Lilly USA, LLC | $27.61 | 2025 | Mounjaro, Zepbound |
| Myovant Sciences INC. | $25.93 | 2021-2022 | |
| Millicent US INC | $23.62 | 2025 | Femlyv |
| Medtronic, INC. | $19.53 | 2022 | |
| Minerva Surgical, INC | $16.13 | 2022 | |
| Sumitomo Pharma America, INC. | $14.73 | 2025 | Myfembree |
| Ibsa Pharma INC. | $14.59 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Lipowich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.